Prostate cancer is the fifth cause of tumor-related deaths in man worldwide. Due to its long latency period, this pathology represents an ideal type of disease for chemopreventive studies. Among the drugs considered thus far for the treatment of prostate cancer, the natural compound resveratrol emerged as very promising. Resveratrol is widely recognized as a chemopreventive agent and was shown to potentiate the antitumor activity of conventional chemotherapeutics in several tumors, including prostate cancer. Here, we overview the literature of the last five years and summarize the recent achievements of resveratrol and its derivatives as antimetastatic agents in prostate cancer. Moreover, drug combination studies as well as nanomedicine approaches proposed to improve resveratrol activity and to overcome delivery drawbacks are addressed. The last part of the review discusses the clinical trials containing resveratrol ongoing on cancer patients.

前列腺癌是全球人类肿瘤相关死亡的第五大原因。由于其较长的潜伏期，这种病理学代表了化学预防研究的理想疾病类型。在迄今为止考虑用于治疗前列腺癌的药物中，天然化合物白藜芦醇非常有前景。白藜芦醇被广泛认为是一种化学预防剂，并被证明可以增强常规化学治疗剂在包括前列腺癌在内的几种肿瘤中的抗肿瘤活性。在这里，我们回顾了过去五年的文献并总结了白藜芦醇及其衍生物作为前列腺癌抗转移剂的最新成就。此外，还提出了药物组合研究以及提出的改善白藜芦醇活性和克服递送缺陷的纳米药物方法。